Literature DB >> 31542259

External Validation of the Model of Thromboembolic Risk in Hypertrophic Cardiomyopathy Patients.

Sen He1, Ziqiong Wang1, Tan Huay Cheem2, Hang Liao3, Xiaoping Chen4, Yong He5.   

Abstract

BACKGROUND: Recently, a new risk model was developed, namely hypertrophic cardiomyopathy (HCM) risk for cerebrovascular accident, for estimating the risk of thromboembolism (TE) in patients with HCM. There is no study about the external validation of this model.
METHODS: We evaluated the performance of the model for predicting TE in 417 patients with HCM recruited between 2008 and 2016, from a tertiary referral centre. The primary end point was 5-year TE, and the risk was calculated using the model formula.
RESULTS: During a median follow-up of 3.5 years, 25 (6.0%) patients reached the TE end point, and 22 (5.3%) patients within the first 5 years. Within a 5-year time frame, the model showed a possibly helpful discrimination for TE (C-index for the whole cohort: 0.67, C-index for the subgroup without atrial fibrillation: 0.67) relative to its original C-index of 0.75. However, the calibration was not perfect, which suggested that there was an underestimation of 5-year TE risk in the whole cohort and different risk groups.
CONCLUSIONS: HCM risk for cerebrovascular accident demonstrated a possibly helpful discrimination for TE when applied in a new set of patients with HCM. However, the accurate estimation of absolute risk should be explored in future studies.
Copyright © 2019 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31542259     DOI: 10.1016/j.cjca.2019.05.035

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  7 in total

Review 1.  Ischaemic events in hypertrophic cardiomyopathy patients with and without atrial fibrillation: a systematic review and meta-analysis.

Authors:  Tiffany T S Ye; Qi Zhuang Siah; Benjamin Y Q Tan; Jamie S Y Ho; Nicholas L X Syn; Yao Hao Teo; Yao Neng Teo; James W Yip; Tiong-Cheng Yeo; Weiqin Lin; Raymond C C Wong; Ping Chai; Bernard Chan; Vijay Kumar Sharma; Leonard L L Yeo; Ching-Hui Sia
Journal:  J Thromb Thrombolysis       Date:  2022-10-03       Impact factor: 5.221

Review 2.  Thromboembolism in Patients with Hypertrophic Cardiomyopathy.

Authors:  Lu Liu; Zheng Liu; Xiaoping Chen; Sen He
Journal:  Int J Med Sci       Date:  2021-01-01       Impact factor: 3.738

Review 3.  Anticoagulation in cardiomyopathy: unravelling the hidden threat and challenging the threat individually.

Authors:  Xiaogang Zhu; Zhenhua Wang; Markus W Ferrari; Katharina Ferrari-Kuehne; Javed Bulter; Xiuying Xu; Quanzhong Zhou; Yuhui Zhang; Jian Zhang
Journal:  ESC Heart Fail       Date:  2021-09-08

4.  Assessing the relationship between systemic immune-inflammation index and mortality in patients with hypertrophic cardiomyopathy.

Authors:  Ziqiong Wang; Haiyan Ruan; Liying Li; Xin Wei; Ye Zhu; Jiafu Wei; Xiaoping Chen; Sen He
Journal:  Ups J Med Sci       Date:  2021-12-03       Impact factor: 2.384

5.  Combined evaluation of coronary artery disease and high-sensitivity cardiac troponin T for prediction of adverse events in patients with hypertrophic cardiomyopathy.

Authors:  Hang Liao; Huay Cheem Tan; Ziqiong Wang; Xiaoping Chen; Yong He; Sen He
Journal:  BMC Cardiovasc Disord       Date:  2021-07-03       Impact factor: 2.298

6.  U-shaped association between serum uric acid concentration and mortality in hypertrophic cardiomyopathy patients.

Authors:  Ziqiong Wang; Ying Xu; Hang Liao; Xiaoping Chen; Sen He
Journal:  Ups J Med Sci       Date:  2020-02-04       Impact factor: 2.384

7.  Myocardial contraction fraction predicts mortality for patients with hypertrophic cardiomyopathy.

Authors:  Hang Liao; Ziqiong Wang; Liming Zhao; Xiaoping Chen; Sen He
Journal:  Sci Rep       Date:  2020-10-12       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.